Bio-Techne Corporation (TECH)

Market Cap	11.23B
Revenue (ttm)	1.15B
Net Income (ttm)	203.00M
Shares Out	157.59M
EPS (ttm)	1.25
PE Ratio	56.99
Forward PE	36.00
Dividend	$0.32 (0.45%)
Ex-Dividend Date	May 10, 2024

Volume	842,253
Open	71.67
Previous Close	71.61
Day's Range	70.96 - 72.35
52-Week Range	51.79 - 89.91
Beta	1.29
Analysts	Buy
Price Target	81.11 (+13.86%)
Earnings Date	Aug 6, 2024

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH

Financial Performance

In 2023, Bio-Techne's revenue was $1.14 billion, an increase of 2.81% compared to the previous year's $1.11 billion. Earnings were $285.26 million, an increase of 4.86%.

Analyst Forecast

According to 10 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $81.11, which is an increase of 13.86% from the latest price.

Price Target

$81.11

(13.86% upside)

Analyst Consensus: Buy